PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2008-06-18. The firm is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. The company is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
PCI Biotech Holding ASA 4QG.BE
€0.02 €0.01 (29.38%) 1D
Last Updated: Dec 17, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
PCI Biotech Holding ASA (4QG.BE) Chart
Financial Metrics & Statements of PCI Biotech Holding ASA (4QG.BE)
FAQ's for PCI Biotech Holding ASA (4QG.BE)
As of September 2026, PCI Biotech Holding ASA 4QG.BE is classified as not covered according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes PCI Biotech Holding ASA using these criteria to determine its compliance status.
Muslim investors may consider investing in PCI Biotech Holding ASA if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of PCI Biotech Holding ASA by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of PCI Biotech Holding ASA may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of PCI Biotech Holding ASA on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for PCI Biotech Holding ASA (4QG.BE)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.